Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. We have discovered and are developing muscle-directed investigational medicines that may potentially improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q1 2026 · $19.4MThe company’s own SEC segment disclosure.
- License And Milestone$11.9M62%
- Net Product$4.8M25%
- Collaboration$2.6M14%
Cytokinetics, Incorporated (CYTK) reported revenue of $29M in Q2 2026 (quarter ended June 30, 2026), down 57% from the same quarter a year earlier. That came with net loss of $199M. For the full year FY2025, revenue was $88M (+377% year on year) and net income −$785M. Its largest product in 2026-Q1 was License And Milestone at $12M, 62% of the disclosed total, just ahead of Net Product at 25%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.